Expertise in
29
conditions

Dr. Kenneth W. Dawes

Dermatology
Dawes Fretzin Dermatology Group LLC
7910 N Shadeland Ave, 
Indianapolis, IN 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
29
conditions
Dawes Fretzin Dermatology Group LLC
7910 N Shadeland Ave, 
Indianapolis, IN 

Overview

Kenneth Dawes is a Dermatologist practicing medicine in Indianapolis, Indiana.

Dr. Dawes is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Neurocutaneous Melanosis, Giant Congenital Melanocytic Nevus, Giant Congenital Nevus, and Familial Atypical Multiple Mole Melanoma Syndrome.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 12 clinical trials. Dr. Dawes is currently accepting new patients.

Specialties

Dermatology

Licenses

Dermatology in IN

Hospital Affiliations

Community Hospital Of Anderson And Madison County

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Chinese Community Health
  • HMO
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 25 Less Insurance Carriers -

Locations

Dawes Fretzin Dermatology Group LLC
7910 N Shadeland Ave, Indianapolis, IN 46250

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
Enrollment Status: Completed
Publish Date: May 11, 2026
Intervention Type: Drug
Study Drug: Orticumab
Study Phase: Phase 2
A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
Enrollment Status: Active_not_recruiting
Publish Date: March 20, 2026
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: February 17, 2026
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
Enrollment Status: Completed
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drug: GSK1070806
Study Phase: Phase 1
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: CDX-0159, Normal Saline
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 28, 2022
Intervention Type: Drug
Study Drug: Naloxone Hydrochloride Lotion
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety, Clinical Effects, and Systemic Exposure of a Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis
A Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety, Clinical Effects, and Systemic Exposure of a Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis
Enrollment Status: Completed
Publish Date: October 05, 2021
Intervention Type: Drug
Study Drug: BMX-010
Study Phase: Phase 2
View 9 Less Clinical Trials

1 Total Publications

Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
Journal: JAMA dermatology
Published: July 20, 2022
Similar Doctors
Expertise in
55
conditions
Expertise in
55
conditions
Referral may be required

Indiana University Health University Hospital

550 University Blvd, 
Indianapolis, IN 
 (10.9 miles away)
317-944-7744
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lawrence Mark is a Dermatologist practicing medicine in Indianapolis, Indiana. Dr. Mark is highly rated in 55 conditions, according to our data. His clinical expertise encompasses Lymphomatoid Papulosis, T-Cell Lymphoma, Mycosis Fungoides, and Anaplastic Large Cell Lymphoma. Dr. Mark is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required
Before you request

Dawes Fretzin Dermatology Group LLC

7910 N Shadeland Ave, 
Indianapolis, IN 
 (0.1 miles away)
317-516-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ann-marie Hyatt is a Dermatologist practicing medicine in Indianapolis, Indiana. Dr. Hyatt is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Neurocutaneous Melanosis, Giant Congenital Melanocytic Nevus, Giant Congenital Nevus, and Familial Atypical Multiple Mole Melanoma Syndrome. Dr. Hyatt is currently accepting new patients.

Expertise in
46
conditions
Expertise in
46
conditions
Referral may be required

Optum - Dermatology

13000 N Meridian St Ste 101, 
Carmel, IN 
 (8.1 miles away)
317-208-3813
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Bridge is a Dermatologist practicing medicine in Carmel, Indiana. Dr. Bridge is highly rated in 46 conditions, according to our data. His clinical expertise encompasses Melanoma, Familial Atypical Multiple Mole Melanoma Syndrome, Giant Congenital Nevus, and Giant Congenital Melanocytic Nevus. Dr. Bridge is board certified in American Board Of Dermatology. Dr. Bridge is currently accepting new patients.

Frequently Asked Questions about Dr. Kenneth W. Dawes

How do I make an appointment with Dr. Kenneth W. Dawes?

You can book an appointment with Dr. Kenneth W. Dawes by calling their office at 317-516-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kenneth W. Dawes a top-rated expert for Neurocutaneous Melanosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kenneth W. Dawes is classified as an Distinguished expert for Neurocutaneous Melanosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kenneth W. Dawes specialize in?

While Dr. Kenneth W. Dawes is a Dermatology, they have specific expertise in Neurocutaneous Melanosis, Giant Congenital Melanocytic Nevus, and Giant Congenital Nevus. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Kenneth W. Dawes participate in research or clinical trials?

Yes. Dr. Kenneth W. Dawes has published 1 articles and abstracts on conditions like Neurocutaneous Melanosis. You can view a list of Dr. Kenneth W. Dawes's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kenneth W. Dawes accept my insurance?

Dr. Kenneth W. Dawes accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 317-516-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dawes's expertise for a condition
ConditionClose
    View All 23 Advanced Conditions
    View All 28 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile